Professor Saul Faust, Advisory Board Member of Stablepharma, receives OBE at Buckingham Palace

Mergermarket Interview with Stablepharma CEO on future IPO and Series B raise

Stablepharma closed Series A funding round of $6.4m to progress fridge-free vaccines and mRNA/LNP stabilisation technologies

Johnny Sutton joins the Stablepharma Ltd Board of Directors

Stablepharma sign exclusive supply agreement to produce the world’s first fridge-free Tetanus diphtheria vaccine

New Data demonstrates StablevaX™-Td Vaccine Stable after 12 months at +45°C

Stablepharma and a World Leader in Sterile Manufacturing Announce Partnership to Manufacture the first Fridge-Free Tetanus diphtheria (Td) Vaccine

How British research could hold the key to taming Monkeypox and fridge-free vaccines

Stablepharma’s CEO is amongst 29 of London’s Most Impressive & Successful Directors in the Biotech Space

A new generation of COVID-19 vaccines – the latest developments from preclinical and clinical trials?

Stablepharma Ltd has achieved a scientific breakthrough, demonstrating that a fridge-free Tetanus diphtheria (Td) vaccine is possible

Stablepharma Ltd welcomes another new member to the UK Team